UBS analyst Jonathan Yong raised the firm’s price target on Alignment Healthcare (ALHC) to $22 from $21 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Analyst Reiterates Buy on Alignment Healthcare as Conservative 2026 EBITDA Outlook and Market-Share Gains Signal Upside Potential
- Alignment Healthcare price target raised to $19 from $18 at Barclays
- Alignment Healthcare reports Q1 EPS 5c, consensus 9c
- Alignment Healthcare sees Q2 revenue $1.3B-$1.32B, consensus $1.31B
- Private Markets: Nuclear, hypersonics score nearly $800M in fresh capital